Hui Hao-Shen

2.8k total citations · 1 hit paper
34 papers, 1.8k citations indexed

About

Hui Hao-Shen is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Hui Hao-Shen has authored 34 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 25 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in Hui Hao-Shen's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Acute Myeloid Leukemia Research (11 papers). Hui Hao-Shen is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Acute Myeloid Leukemia Research (11 papers). Hui Hao-Shen collaborates with scholars based in Switzerland, United States and Austria. Hui Hao-Shen's co-authors include Radek C. Skoda, Ralph Tiedt, Renate Looser, Stephan Dirnhofer, Tibor Schomber, Marta Sobas, Jürg Schwaller, Thomas Lehmann, Pontus Lundberg and Róbert Královics and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Hui Hao-Shen

34 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

2014 401 citations Pontus Lundberg, Axel Karow et al. Blood profile →

Peers

Hui Hao-Shen

GENET

HEMAT

RHEUM

IMMUN

Rachel Okabe United States

Sandra Moore United States

Emnet A Wassie United States

Takefumi Ishii United States

Damla Olcaydu Austria

Marjorie Boissinot United Kingdom

Harini Nivarthi Austria

Dominique Bluteau France

Annalisa Pacilli Italy

Hédia Chagraoui France

Rachel Okabe United States

Hui Hao-Shen

1.0k ×0.7

GENET

1.0k ×0.8

HEMAT

1.2k ×1.2

332 ×0.7

RHEUM

224 ×1.4

IMMUN

Citations per year, relative to Hui Hao-Shen Hui Hao-Shen (= 1×) peers Rachel Okabe

Countries citing papers authored by Hui Hao-Shen

Since Specialization

Citations

This map shows the geographic impact of Hui Hao-Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Hao-Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Hao-Shen more than expected).

Fields of papers citing papers by Hui Hao-Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui Hao-Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Hao-Shen. The network helps show where Hui Hao-Shen may publish in the future.

Co-authorship network of co-authors of Hui Hao-Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Hui Hao-Shen. A scholar is included among the top collaborators of Hui Hao-Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui Hao-Shen. Hui Hao-Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rai, Shivam, Yang Zhang, Nils Hansen, et al.. (2024). IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Advances. 8(5). 1234–1249. 15 indexed citations

Hansen, Nils, Alexandre Guy, Shivam Rai, et al.. (2024). The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Advances. 8(9). 2312–2325. 8 indexed citations

Paz, Damien Luque, Nils Hansen, Lucia Kubovčáková, et al.. (2024). Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F–positive myeloproliferative neoplasms. Blood. 143(24). 2490–2503. 3 indexed citations

Paz, Damien Luque, Ronny Nienhold, Shivam Rai, et al.. (2023). Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms. HemaSphere. 7(5). e885–e885. 5 indexed citations

Almeida, Tiago O., Julien Roux, Athimed El Taher, et al.. (2023). Cellular Barcoding of JAK2-V617F Hematopoietic Stem Cells Reveals No Substantial Preferences in the Contribution of Individual Stem Cell Clones to Erythroid Versus Megakaryocytic Lineages. Blood. 142(Supplement 1). 859–859. 1 indexed citations

Rai, Shivam, Nils Hansen, Damien Luque Paz, et al.. (2022). Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nature Communications. 13(1). 5346–5346. 37 indexed citations

Hansen, Nils, et al.. (2020). Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2-V617F Mouse Model. Blood. 136(Supplement 1). 8–9. 1 indexed citations

Rai, Shivam, et al.. (2019). IL-1β Secreted from Mutant Cells Carrying JAK2-V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression. Blood. 134(Supplement_1). 307–307. 13 indexed citations

Stivala, Simona, Šime Brkić, Anne Baerenwaldt, et al.. (2019). Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. Journal of Clinical Investigation. 129(4). 1596–1611. 72 indexed citations

10.

Meyer, Sara C., Simona Stivala, Anne Baerenwaldt, et al.. (2017). Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms. Bern Open Repository and Information System (University of Bern). 4 indexed citations

11.

Shimizu, Takafumi, Lucia Kubovčáková, Ronny Nienhold, et al.. (2016). Loss of Ezh2 synergizes with JAK2 -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. The Journal of Experimental Medicine. 213(8). 1479–1496. 82 indexed citations

12.

Grisouard, Jean, Takafumi Shimizu, Adrian Duek, et al.. (2015). Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 125(13). 2131–2140. 36 indexed citations

13.

Lundberg, Pontus, Hitoshi Takizawa, Lucia Kubovčáková, et al.. (2014). Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2 -V617F. The Journal of Experimental Medicine. 211(11). 2213–2230. 69 indexed citations

14.

Duek, Adrian, Pontus Lundberg, Takafumi Shimizu, et al.. (2014). Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F–driven mouse model of MPNs. Blood. 123(25). 3943–3950. 34 indexed citations

15.

Kubovčáková, Lucia, Pontus Lundberg, Jean Grisouard, et al.. (2012). Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 121(7). 1188–1199. 32 indexed citations

16.

Lundberg, Pontus, Lucia Kubovčáková, Hitoshi Takizawa, et al.. (2011). JAK2-V617F Expressing Stem Cells Display a Competitive Advantage At Low Limiting Dilution and Are Capable of Initiating MPN Phenotype. Blood. 118(21). 615–615. 2 indexed citations

17.

Tiedt, Ralph, Jörn Coers, Sandra Ziegler, et al.. (2008). Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood. 113(8). 1768–1777. 44 indexed citations

18.

Theocharides, Alexandre, Jakob Passweg, Michael Medinger, et al.. (2008). The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 93(12). 1890–1893. 30 indexed citations

19.

Schaub, Franz X., Roland Jäger, Renate Looser, et al.. (2008). Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 113(9). 2022–2027. 50 indexed citations

20.

Tiedt, Ralph, Tibor Schomber, Hui Hao-Shen, & Radek C. Skoda. (2006). Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 109(4). 1503–1506. 311 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact